AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05677568 — intervention group
Intervention type: DEVICE
Intervention: Carillon Mitral Contour System
Description: The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.
Study NCT02733640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: pantoprazole 40 mg once-daily
Study NCT02733640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: ranitidine 150 mg twice-daily
Study NCT02481219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam® COLON 2 procedure-CONTROL
Study NCT02481219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure-CONTROL
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna tablets
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna tablets
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUPREP oral sulfate solution
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study NCT02481219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP oral sulfate solution with Gastrografin
Study NCT02797938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taper guard tube
Description: Taper guard tube was intubated
Study NCT02797938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical tube
Description: Cylindrical tube was intubated
Study NCT04342325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of ADR-001 (Mesenchymal stem cell)
Description: Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
Study NCT03754998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
Study NCT02664896 — intervention group
Intervention type: OTHER
Intervention: Knee Osteoarthritis
Description: Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
Study NCT02664896 — intervention group
Intervention type: OTHER
Intervention: Healthy Control
Description: Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
Study NCT02203968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate
Description: Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Study NCT02203968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Study NCT02753504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Study NCT02753504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03239106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg BID daily
Study NCT00714870 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral nutrition and exercise program
Description: The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
Study NCT01441232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: 400 mg of LX4211 administered as two 200 mg tablets
Study NCT01441232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia®
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Study NCT01441232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia®
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Study NCT01140126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody UB-421
Description: Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
Study NCT02894684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam
Description: 14 days of AZLI: 75mg TDS PLUS IV Colistin
Study NCT02894684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: 14 days of AZLI: 75mg TDS PLUS IV Colistin
Study NCT02894684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: 14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
Study NCT02894684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: 14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
Study NCT03949803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Chocolate Timing
Description: During two consecutive weeks volunteers will eat chocolate within 1 hour of their habitual wake-time (100g).
Study NCT03949803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening Chocolate Timing
Description: During two consecutive weeks volunteers will eat chocolate within 1 hours of habitual bedtime (100g).
Study NCT03949803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Chocolate Timing
Description: During two consecutive weeks volunteers will not eat chocolate.
Study NCT00721383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Physical Activity Intervention
Description: Physical activity and caregiver skill-building
Study NCT00721383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSBI
Description: Caregiver skill-building
Study NCT01459497 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
Study NCT01459497 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation
Description: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
Study NCT00659789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study NCT00659789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water is used in place of Vacc-4x and in place of Leukine
Study NCT00030914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone
Study NCT00030914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Study NCT03854279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tonsillar dissection
Description: The tonsils will be removed by bizact device
Study NCT03854279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillar dissection
Description: The tonsils will be removed by bizact device
Study NCT04298671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-Pilates
Description: As above
Study NCT02853058 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: normal PI
Description: measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
Study NCT02853058 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: pathological PI
Description: measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
Study NCT02881606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Naso-alveolar molding (NAM)
Study NCT02881606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer aided design NAM (CAD/NAM)
Study NCT01586572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mOPV1
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
Study NCT01586572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bOPV 1,3
Description: The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
Study NCT01129596 — intervention group
Intervention type: DRUG
Intervention: donepezil hydrochloride
Description: This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
Study NCT03614156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
Study NCT03614156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration)
Study NCT01876017 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of Autologous (BMMNCs)
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
Study NCT04287517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capacitive-Resistive Therapy
Description: Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
Study NCT04287517 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Capacitive-Resistive Therapy
Description: Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
Study NCT01321099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Description: Labeled iron as FeSO4 or NaFeEDTA added to a test meal
Study NCT01321099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytase
Description: Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
Study NCT01321099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Labeled iron as FeSO4 added to a test meal with or without vitamin C
Study NCT04615832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee Full Face Mask
Description: Full face mask for PAP therapy applied in a home environment
Study NCT03530124 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
Study NCT03530124 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP
Description: ACIP Recommended vaccine
Study NCT03530124 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBV
Description: ACIP Recommended vaccine
Study NCT03530124 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IPV
Description: ACIP Recommended vaccine
Study NCT03530124 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hib
Description: ACIP Recommended vaccine
Study NCT03292367 — intervention group
Intervention type: PROCEDURE
Intervention: ldTRA
Description: After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
Study NCT01543048 — intervention group
Intervention type: OTHER
Intervention: Study Follow-Up
Description: Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
Study NCT01145976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cy-ATG
Description: Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
Study NCT01145976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu-ATG
Description: Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
Study NCT02745119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
Study NCT03651414 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Description: There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
Study NCT02979548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
Study NCT02979548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
Study NCT02979548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
Study NCT02979548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
Study NCT02979548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
Study NCT00183313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse case management
Description: Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
Study NCT00183313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes standard mental health services.
Study NCT02980393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
Study NCT03863769 — intervention group
Intervention type: OTHER
Intervention: Lumbar Spinal Stenosis
Description: Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
Study NCT01579136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor
Description: The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
Study NCT03229980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold blood cardioplegia (large volume)
Description: Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
Study NCT03229980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold blood cardioplegia (small volume)
Description: Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
Study NCT02425943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid Sculptra Aesthetic
Study NCT03016052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
Study NCT00904592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi ming granula
Description: Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
Study NCT00904592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid
Study NCT00357903 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Etanercept
Description: Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
Study NCT01405144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: 5% 5-fluoruracil cream, twice a day, during 3 weeks
Study NCT01405144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
Study NCT03714880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 MG
Description: Ingestion of study medication vs placebo
Study NCT03714880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Ingestion of study medication vs placebo